Shopping Cart
- Remove All
- Your shopping cart is currently empty
Belumosudil mesylate (KD025 mesylate) is a selective and highly efficient ROCK2 inhibitor with antifibrotic activity. It inhibits ROCK1 and can be used in chronic graft-versus-host disease research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
5 mg | $68 | In Stock | |
10 mg | $109 | In Stock | |
25 mg | $182 | In Stock | |
50 mg | $268 | In Stock | |
100 mg | $396 | In Stock | |
500 mg | $943 | In Stock |
Description | Belumosudil mesylate (KD025 mesylate) is a selective and highly efficient ROCK2 inhibitor with antifibrotic activity. It inhibits ROCK1 and can be used in chronic graft-versus-host disease research. |
Targets&IC50 | ROCK2:105 nM (IC50), ROCK1:24 μM (IC50) |
In vitro | Belumosudil mesylate is a selective inhibitor of ROCK2, with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively.[1] 40 μM Belumosudil mesylate significantly down-regulated the levels of Tsp-1 and CTGF mRNA in pulmonary artery smooth muscle cells (PASMC). [1] |
In vivo | Intraperitoneal injection of 100, 200, or 300 mg/kg Belumosudil mesylate dose-dependently reduced infarct volume after transient middle cerebral artery occlusion. Belumosudil mesylate was at least as effective in aged, diabetic, or female mice as in normal adult male mice. [2] |
Alias | SLx-2119 mesylate, SLx2119 mesylate, SAR445761, Rezurock Rezurock, KD025 mesylate, KD 025 mesylate |
Molecular Weight | 548.61 |
Formula | C27H28N6O5S |
Cas No. | 2109704-99-4 |
Smiles | O=C(NC(C)C)COC1=CC=CC(=C1)C=2N=C3C=CC=CC3=C(N2)NC=4C=CC=5NN=CC5C4.O=S(=O)(O)C |
Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 8.00 mg/mL (14.58 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.